Knockdown of ANLN inhibits the progression of lung adenocarcinoma via pyroptosis activation

Sheng,Li; Kang,Yanhai; Chen,Denglin; Shi,Linyang

doi:10.3892/mmr.2023.13064

Knockdown of ANLN inhibits the progression of lung adenocarcinoma via pyroptosis activation

Authors:
- Li Sheng
- Yanhai Kang
- Denglin Chen
- Linyang Shi
View Affiliations

Affiliations: Department of Medical Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China, Department of Psychology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China
Published online on: August 3, 2023 https://doi.org/10.3892/mmr.2023.13064
Article Number: 177
Copyright: © Sheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Significant advancements have been achieved in the area of molecular targeted therapy for lung adenocarcinoma (LUAD). However, the complex molecular patterns and high heterogeneity of LUAD confine the efficacy of these therapies to a specific subset of patients; therefore, it is necessary to explore novel targets for LUAD treatment. The expression levels of anillin (ANLN) in LUAD were analyzed using the Gene Expression Profiling Interactive Analysis database. Furthermore, the association between ANLN gene expression and patient survival outcomes was evaluated using the Kaplan‑Meier Plotter. Subsequently, small interfering RNA (siRNA) transfection was performed to knock down ANLN in A549 and H1299 cell lines, after which, TUNEL, colony formation and Transwell assays were conducted to assess cell death, colony formation and migration, respectively. Additionally, western blot analysis was performed to analyze the expression levels of caspase‑1, interleukin (IL)‑18 (IL‑18), IL‑1β, NLR family pyrin domain‑containing 3 (NLRP3), apoptosis‑associated speck‑like protein containing a CARD domain (ASC) and cleaved gasdermin D (GSDMD) following ANLN knockdown. The results revealed that ANLN mRNA expression was significantly increased in LUAD tissues compared with adjacent normal samples. Furthermore, the expression levels of ANLN displayed an increasing trend with advancing clinical stage. Furthermore, patients with high ANLN expression levels exhibited poor overall survival rates compared with those with low ANLN expression levels. Subsequent ANLN knockdown experiments indicated elevated cell death rate, and reduced colony formation and migration in both A549 and H1299 cells. Additionally, ANLN knockdown resulted in increased protein expression levels of pyroptosis‑associated molecules, including caspase‑1, NLRP3, cleaved‑GSDMD, IL‑1β, ASC and IL‑18 in both A549 and H1299 cells. In conclusion, ANLN represents an important gene and a promising therapeutic target for LUAD. Its potential as a therapeutic target makes it an interesting candidate for further exploration in the development of novel treatment strategies for LUAD.

View Figures

View References

1	Szczepanski AP, Tsuboyama N, Watanabe J, Hashizume R, Zhao Z and Wang L: POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity. Sci Adv. 8:eabq24032022. View Article : Google Scholar : PubMed/NCBI
2	Wang Y, Ren F, Sun D, Liu J, Liu B, He Y, Pang S, Shi B, Zhou F, Yao L, et al: CircKEAP1 suppresses the progression of lung adenocarcinoma via the miR-141-3p/KEAP1/NRF2 axis. Front Oncol. 11:6725862021. View Article : Google Scholar : PubMed/NCBI
3	Yuan J, Yuan B, Zeng L, Liu B, Chen Y, Meng X, Sun R, Lv X, Wang W and Yang S: Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma. Oncol Lett. 20:1772–1780. 2020. View Article : Google Scholar : PubMed/NCBI
4	Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018. View Article : Google Scholar : PubMed/NCBI
5	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
6	Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, et al: Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. J Clin Oncol. 33:992–999. 2015. View Article : Google Scholar : PubMed/NCBI
7	Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436. 2022. View Article : Google Scholar : PubMed/NCBI
8	Jia H, Gao Z, Yu F, Guo H and Li B: Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice. Exp Ther Med. 21:4542021. View Article : Google Scholar : PubMed/NCBI
9	Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, et al: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 99:16899–16903. 2002. View Article : Google Scholar : PubMed/NCBI
10	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, et al: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 36:40–45. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lian YF, Huang YL, Wang JL, Deng MH, Xia TL, Zeng MS, Chen MS, Wang HB and Huang YH: Anillin is required for tumor growth and regulated by miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma. Aging (Albany NY). 10:1884–1901. 2018. View Article : Google Scholar : PubMed/NCBI
12	Deng F, Xu Z, Zhou J, Zhang R and Gong X: ANLN Regulated by miR-30a-5p mediates malignant progression of lung adenocarcinoma. Comput Math Methods Med. 2021:95492872021. View Article : Google Scholar : PubMed/NCBI
13	Luo C, Lei M and Zhang Y, Zhang Q, Li L, Lian J, Liu S, Wang L, Pi G and Zhang Y: Systematic construction and validation of an immune prognostic model for lung adenocarcinoma. J Cell Mol Med. 24:1233–1244. 2020. View Article : Google Scholar : PubMed/NCBI
14	Deng Y, Chen X, Huang C, Song J, Feng S, Chen X and Zhou R: Screening and validation of significant genes with poor prognosis in pathologic stage-I lung adenocarcinoma. J Oncol. 2022:37940212022. View Article : Google Scholar : PubMed/NCBI
15	Zhang L, Luo Y, Cheng T, Chen J, Yang H, Wen X, Jiang Z, Li H and Pan C: Development and validation of a prognostic N6-methyladenosine-related immune gene signature for lung adenocarcinoma. Pharmgenomics Pers Med. 14:1549–1563. 2021.PubMed/NCBI
16	Broz P, Pelegrin P and Shao F: The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 20:143–157. 2020. View Article : Google Scholar : PubMed/NCBI
17	Lin W, Chen Y, Wu B, Chen Y and Li Z: Identification of the pyroptosis-related prognostic gene signature and the associated regulation axis in lung adenocarcinoma. Cell Death Discov. 7:1612021. View Article : Google Scholar : PubMed/NCBI
18	Gu H, Deng W, Zhang Y, Chang Y, Shelat VG, Tsuchida K, Lino-Silva LS and Wang Z: NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma. Transl Lung Cancer Res. 11:858–868. 2022. View Article : Google Scholar : PubMed/NCBI
19	Gao J, Qiu X, Xi G, Liu H, Zhang F, Lv T and Song Y: Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer. Oncol Rep. 40:1971–1984. 2018.PubMed/NCBI
20	Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Rep. 35:2053–2064. 2016. View Article : Google Scholar : PubMed/NCBI
21	Dai X, Chen X, Hakizimana O and Mei Y: Genetic interactions between ANLN and KDR are prognostic for breast cancer survival. Oncol Rep. 42:2255–2266. 2019.PubMed/NCBI
22	Wang Y, Zhang JW, Wang JW, Wang JL, Zhang SC, Ma RY, Zhang J, Li Y, Liu PJ, Xue WJ, et al: BMSCs overexpressed ISL1 reduces the apoptosis of islet cells through ANLN carrying exosome, INHBA, and caffeine. Cell Mol Life Sci. 79:5382022. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Harrison PT, Vyse S and Huang PH: Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 61:167–179. 2020. View Article : Google Scholar : PubMed/NCBI
25	Muller IB, de Langen AJ, Giovannetti E and Peters GJ: Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: Clinical impact of alectinib. Onco Targets Ther. 10:4535–4541. 2017. View Article : Google Scholar : PubMed/NCBI
26	Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, et al: Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 3:630–635. 2013. View Article : Google Scholar : PubMed/NCBI
27	Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
28	Tan AC and Tan DSW: Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 40:611–625. 2022. View Article : Google Scholar : PubMed/NCBI
29	Hall G, Lane BM, Khan K, Pediaditakis I, Xiao J, Wu G, Wang L, Kovalik ME, Chryst-Stangl M, Davis EE, et al: The human FSGS-causing ANLN R431C mutation induces dysregulated PI3K/AKT/mTOR/Rac1 signaling in podocytes. J Am Soc Nephrol. 29:2110–2122. 2018. View Article : Google Scholar : PubMed/NCBI
30	Shi Y, Ma X, Wang M, Lan S, Jian H, Wang Y, Wei Q and Zhong F: Comprehensive analyses reveal the carcinogenic and immunological roles of ANLN in human cancers. Cancer Cell Int. 22:1882022. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Chen L, Ju L, Qian K, Liu X, Wang X and Xiao Y: Novel biomarkers associated with progression and prognosis of bladder cancer identified by co-expression analysis. Front Oncol. 9:10302019. View Article : Google Scholar : PubMed/NCBI
32	Zhang F, Cai J, Hu K, Liu W, Lu S, Tang B, Li M, Wu W, Ren Z and Yin X: An immune-related gene signature predicting prognosis and immunotherapy response in hepatocellular carcinoma. Comb Chem High Throughput Screen. 25:2203–2216. 2022. View Article : Google Scholar : PubMed/NCBI
33	Wang G, Shen W, Cui L, Chen W, Hu X and Fu J: Overexpression of Anillin (ANLN) is correlated with colorectal cancer progression and poor prognosis. Cancer Biomark. 16:459–465. 2016. View Article : Google Scholar : PubMed/NCBI
34	Guo E, Mao X, Wang X, Guo L, An C, Zhang C, Song K, Wang G, Duan C, Zhang X, et al: Alternatively spliced ANLN isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma. Cell Death Dis. 12:7642021. View Article : Google Scholar : PubMed/NCBI
35	Liu Y, Cao P, Cao F, Wang S, He Y, Xu Y and Wang Y: ANLN, regulated by SP2, promotes colorectal carcinoma cell proliferation via PI3K/AKT and MAPK signaling pathway. J Invest Surg. 35:268–277. 2022. View Article : Google Scholar : PubMed/NCBI
36	Wang Z, Hu S, Li X, Liu Z, Han D, Wang Y, Wei L, Zhang G and Wang X: MiR-16-5p suppresses breast cancer proliferation by targeting ANLN. BMC Cancer. 21:11882021. View Article : Google Scholar : PubMed/NCBI
37	Yu P, Zhang X, Liu N, Tang L, Peng C and Chen X: Pyroptosis: Mechanisms and diseases. Signal Transduct Target Ther. 6:1282021. View Article : Google Scholar : PubMed/NCBI
38	Man SM and Kanneganti TD: Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 16:7–21. 2016. View Article : Google Scholar : PubMed/NCBI
39	Brocker CN, Kim D, Melia T, Karri K, Velenosi TJ, Takahashi S, Aibara D, Bonzo JA, Levi M, Waxman DJ and Gonzalez FJ: Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nat Commun. 11:58472020. View Article : Google Scholar : PubMed/NCBI
40	Tsuchiya K, Nakajima S, Hosojima S, Thi Nguyen D, Hattori T, Manh Le T, Hori O, Mahib MR, Yamaguchi Y, Miura M, et al: Caspase-1 initiates apoptosis in the absence of gasdermin D. Nat Commun. 10:20912019. View Article : Google Scholar : PubMed/NCBI
41	Paik S, Kim JK, Silwal P, Sasakawa C and Jo EK: An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 18:1141–1160. 2021. View Article : Google Scholar : PubMed/NCBI
42	Looi CK, Hii LW, Chung FF, Mai CW, Lim WM and Leong CO: Roles of inflammasomes in Epstein-Barr virus-associated nasopharyngeal cancer. Cancers (Basel). 13:17862021. View Article : Google Scholar : PubMed/NCBI
43	Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F and Shao F: Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 526:660–665. 2015. View Article : Google Scholar : PubMed/NCBI
44	Evavold CL, Hafner-Bratkovič I, Devant P, D'Andrea JM, Ngwa EM, Boršić E, Doench JG, LaFleur MW, Sharpe AH, Thiagarajah JR and Kagan JC: Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway. Cell. 184:4495–4511.e19. 2021. View Article : Google Scholar : PubMed/NCBI
45	de Vasconcelos NM, Van Opdenbosch N, Van Gorp H, Parthoens E and Lamkanfi M: Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. Cell Death Differ. 26:146–161. 2019. View Article : Google Scholar : PubMed/NCBI
46	Xi H, Zhang Y, Xu Y, Yang WY, Jiang X, Sha X, Cheng X, Wang J, Qin X, Yu J, et al: Caspase-1 inflammasome activation mediates homocysteine-induced pyrop-apoptosis in endothelial cells. Circ Res. 118:1525–1539. 2016. View Article : Google Scholar : PubMed/NCBI
47	Zhang MY, Jiang YX, Yang YC, Liu JY, Huo C, Ji XL and Qu YQ: Cigarette smoke extract induces pyroptosis in human bronchial epithelial cells through the ROS/NLRP3/caspase-1 pathway. Life Sci. 269:1190902021. View Article : Google Scholar : PubMed/NCBI
48	Fu X, Hong W, Li S, Chen Z, Zhou W, Dai J, Deng X, Zhou H, Li B and Ran P: Wood smoke particulate matter (WSPM2.5) induces pyroptosis through both caspase-1/IL-1β/IL-18 and ATP/P2Y-dependent mechanisms in human bronchial epithelial cells. Chemosphere. 307:1357262022. View Article : Google Scholar : PubMed/NCBI
49	Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP, Muszyński A, et al: Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 341:1246–1249. 2013. View Article : Google Scholar : PubMed/NCBI
50	Knodler LA, Crowley SM, Sham HP, Yang H, Wrande M, Ma C, Ernst RK, Steele-Mortimer O, Celli J and Vallance BA: Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe. 16:249–256. 2014. View Article : Google Scholar : PubMed/NCBI